Celltrion Pharm announced on the 15th that its sales for the first quarter of this year reached approximately KRW 112.5 billion, marking a 16% increase compared to the same period last year and setting a new record for the highest quarterly performance in the company's history.
During the same period, operating profit surged by 191% to about KRW 10.7 billion. The operating margin also improved by more than 5 percentage points year-on-year, reaching 9.5%. Despite increases in headcount and R&D expenses, Celltrion Pharm achieved higher profitability through cost reductions in commissions and in-house production. Notably, both the chemical and biosimilar divisions, which are the company's core businesses, posted double-digit growth rates of 27% and 14%, respectively, contributing significantly to the record-high sales.
The chemical business division recorded total sales of approximately KRW 51.6 billion. The mainstay liver supplement 'Godex' grew by about 10% year-on-year to KRW 16.2 billion, while 'Dilatrend Tab,' an antihypertensive drug that began full-scale sales last year, posted KRW 13.3 billion in sales, accelerating growth. In addition, the diabetes treatment 'Nesina,' which underwent in-house production, grew by about 157% to KRW 3.3 billion, while 'Actos' grew by about 32% to KRW 5.2 billion. The antihypertensive drug 'Edarbi' also maintained sales of around KRW 2.2 billion.
The biosimilar business division achieved total sales of approximately KRW 20.8 billion. The autoimmune disease treatment 'Remsima SC,' which was converted from an intravenous (IV) to a subcutaneous (SC) formulation, grew by 8% year-on-year and contributed to total sales of KRW 9.2 billion for the Remsima product line. The autoimmune disease treatment 'Yuflyma' also grew by 161% year-on-year to about KRW 1.3 billion. In the oncology sector, 'Herzuma' grew by 18% to about KRW 5.7 billion, while 'Begzelma' increased by 164% to about KRW 1.4 billion in sales.
Additionally, new biosimilar products such as the autoimmune disease treatment 'Stekima,' the ophthalmic disease treatment 'Eydengelth,' and the allergic asthma treatment 'Omriclo,' which were launched last year, are gradually gaining traction in the market as their sales become increasingly visible. Celltrion Pharm plans to continue the growth of its biosimilar business division through active marketing of these products, as well as newly launched bone disease treatments such as 'Stovoclo' and 'Osenbelt' this year, alongside strict quality control.
In the contract manufacturing division, the commercial production of PFS (Prefilled Syringe) products such as the autoimmune disease treatments 'Zympentra' (the US brand name for Remsima SC) and 'Yuflyma,' which are supplied to major global markets, increased significantly, resulting in sales of about KRW 18.9 billion, a 37% increase compared to the same period last year.
Celltrion Pharm stated that it aims to drive sales growth by enhancing product competitiveness and expanding contract manufacturing, while also securing differentiated competitiveness through active investment in research and development (R&D). In the contract manufacturing division, the demand for major SC (subcutaneous) products such as Remsima SC and Yuflyma, which Celltrion supplies to the global market, is rapidly increasing, so continued growth is expected for the time being. The company also anticipates an expansion in production capacity (CAPA) through production facility optimization. In the R&D division, Celltrion Pharm recently attracted attention by presenting research results on its dual payload (cytotoxic anticancer drug) platform technology for antibody-drug conjugates (ADC) at the American Association for Cancer Research (AACR 2025), the world’s largest cancer conference.
A Celltrion Pharm representative stated, "In the first quarter, we achieved record-high sales, with stable growth of existing products and successful market entry of new products standing out," and added, "We will continue our growth momentum based on product competitiveness and high-quality production capabilities, while striving to generate long-term results through the development of new products and expansion of production."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
